Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study-Reference-Cited by-同舟云学术

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Published:2022-04 Issue:1 Volume:165 Page:40-48
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Trillsch Fabian,Mahner Sven,Ataseven Beyhan,Asher Rebecca,Aryal Nanda,Dubot Coraline,Clamp Andrew,Penson Richard T.,Oza Amit,Amit Amnon,Huzarski Tomasz,Casado Antonio,Scambia Giovanni,Friedlander Michael,Colombo Nicoletta,Fujiwara Keiichi,Sonke Gabe S.,Denys Hannelore,Lowe Elizabeth S.,Lee Chee K.,Pujade-Lauraine Eric

Funder

AstraZeneca PLC

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference31 articles.

1. Fifth ovarian cancer consensus conference of the Gynecologic Cancer InterGroup: recurrent disease;Wilson;Ann. Oncol.,2017

2. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer;Ledermann;N. Engl. J. Med.,2012

3. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial;Ledermann;Lancet Oncol.,2014

4. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer;Mirza;N. Engl. J. Med.,2016

5. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial;Coleman;Lancet,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial;Gynecologic Oncology;2024-08

2. Entwicklung einer akuten myeloischen Leukämie unter adjuvanter Therapie mit Olaparib nach neoadjuvanter Chemotherapie eines triple-negativen Mammakarzinoms – eine Kasuistik;Die Gynäkologie;2024-05-13

3. PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer;Cancers;2024-02-25

4. Safety of PARP inhibitors as maintenance therapy in ovarian cancer;Expert Opinion on Drug Safety;2023-09-14

5. Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data;American Society of Clinical Oncology Educational Book;2023-06